Should the MUHC use low-molecular-weight heparin in inpatient treatment of deep vein thrombosis with or without pulmonary embolism?
Chen J, Penrod J, McGregor M
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Chen J, Penrod J, McGregor M. Should the MUHC use low-molecular-weight heparin in inpatient treatment of deep vein thrombosis with or without pulmonary embolism? Technology Assessment Unit of the McGill University Health Centre (MUHC). Report #5. 2003
Authors' objectives
This report compares the effectiveness and safety of low-molecular-weight heparin (LMWH) with unfractionated heparin (UFH) in the in-patient treatment of deep vein thrombosis (DVT) with or without pulmonary embolism (PE), compares their direct costs to the MUHC, and formulates recommendations concerning the use of LMWH for inpatient treatment of these indications.
Authors' conclusions
The TAU Committee recommends that the MUHC approve the replacement, when clinically indicated, of unfractionated heparin by low-molecular-weight heparin for the inpatient treatment of deep vein thrombosis, with or without pulmonary embolism.
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5 Email: nandini.dendukuri@mcgill.ca